Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Genetics topic
No spam. Unsubscribe anytime.
Committee approves bill to remove cost sharing for clinically‑appropriate genetic tests and related screening
Summary
Senators advanced House Bill 1079 to require insurers to eliminate cost sharing for clinically appropriate genetic tests and follow‑up screening; sponsor and survivors said earlier detection and tailored treatment could save lives and control downstream costs.
The Senate Insurance & Commerce Committee approved House Bill 1079, which would require insurers to cover clinically appropriate genetic tests and the follow‑up screenings those tests recommend without cost sharing when medically appropriate, supporters said.
Sponsor and testimony Sponsor Senator Dave Wallace described the bill as a “life‑saving” measure and said stakeholders worked collaboratively on the language. Representative Fred Allen (co‑sponsor) and physician testimony supported the bill.
Dr. Sam McCool, director of clinical research and genomics (testifying as a subject‑matter expert), told the committee that a limited panel of genetic tests — not full genome sequencing — can be performed for a few hundred dollars and can identify inherited mutations that materially change screening and treatment strategies. Dr. McCool said about 20,000 Arkansans will receive a cancer diagnosis this year and that roughly 10 percent of those cases may stem from an inherited mutation; he said earlier testing allows for targeted surveillance of families and can improve outcomes.
Lindsey Penn, a cancer survivor and volunteer with the American Cancer Society Cancer Action Network, testified that genetic testing informed her care and that removing cost barriers would make precision treatment and earlier detection more widely available. Sponsor testimony included a projected cost increase to private insurers of less than $1 per member per month, presented as an illustrative estimate by supporters.
Committee action and next steps After brief questions from committee members concerned about cumulative mandated coverage costs, the committee approved the bill as amended on a voice vote. Sponsors and supporters said there is no direct state budget cost in the bill because it targets private insurance coverage; testimony asserted potential downstream cost savings through earlier detection and more targeted treatment.
Ending The committee approved the measure; proponents said the law would align coverage with current clinical practice and that rulemaking or guidance may follow to specify covered tests and clinical criteria.
